Stock RARE ULTRAGENYX PHARMACEUTICAL INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
43.38 USD -1.65% Intraday chart for Ultragenyx Pharmaceutical Inc. -14.44% -9.28%
Apr. 15 Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup DJ
Apr. 15 Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement' MT

Business Summary

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Number of employees: 1,276

Sales per Business

USD in Million2022Weight2023Weight Delta
Crysvita Royalty
42.1 %
22 6.0 % 183 42.1 % +742.02%
Crysvita
17.4 %
43 11.7 % 76 17.4 % +77.37%
Dojolvi
16.3 %
56 15.3 % 71 16.3 % +27.01%
Collaboration and License - Crysvita Collaboration Revenue in Profit-share Territory
16.1 %
215 59.2 % 70 16.1 % -67.58%
Mepsevii
7.0 %
21 5.7 % 30 7.0 % +47.51%
Evkeeza
0.8 %
- - 4 0.8 % -
Collaboration and License - Daiichi Sankyo
0.3 %
8 2.1 % 1 0.3 % -80.76%

Sales per region

USD in Million2022Weight2023Weight Delta
North America
70.7 %
281 77.4 % 307 70.7 % +9.27%
Latin America
17.8 %
45 12.3 % 77 17.8 % +72.98%
Europe
10.9 %
36 10.0 % 48 10.9 % +30.70%
Japan
0.5 %
1 0.3 % 2 0.5 % +91.56%

Managers

Managers TitleAgeSince
Emil Kakkis FOU
 Founder 63 10-04-21
Howard Horn DFI
 Director of Finance/CFO 47 23-10-15
Eric Crombez CTO
 Chief Tech/Sci/R&D Officer - 17-10-31
Dennis Huang CTO
 Chief Tech/Sci/R&D Officer 59 15-04-30
Samuel C. Wadsworth CTO
 Chief Tech/Sci/R&D Officer 75 17-10-31
Joshua Higa IRC
 Investor Relations Contact - -
Ernie Meyer HRO
 Human Resources Officer 60 20-08-31
Karah Parschauer LAW
 General Counsel 46 16-06-19
Vimal Srivastava PRN
 Corporate Officer/Principal 58 11-07-31
Erik Harris PRN
 Corporate Officer/Principal 54 16-12-31

Members of the board

Members of the board TitleAgeSince
Deborah Dunsire BRD
 Director/Board Member 61 17-04-05
Emil Kakkis FOU
 Founder 63 10-04-21
Daniel Welch CHM
 Chairman 66 15-04-07
Matthew Fust BRD
 Director/Board Member 59 13-12-31
Michael Narachi BRD
 Director/Board Member 64 15-02-19
Corazon Sanders BRD
 Director/Board Member 67 21-06-28
Shehnaaz Suliman BRD
 Director/Board Member 52 19-01-29
Amrit Ray BRD
 Director/Board Member 51 22-04-18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 82,345,246 78,952,476 ( 95.88 %) 9,559 ( 0.0116 %) 95.88 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
10.53 %
8,673,432 10.53 % 405 M $
RTW Investments LP
8.365 %
6,887,086 8.365 % 322 M $
BlackRock Advisors LLC
5.894 %
4,852,526 5.894 % 227 M $
Wellington Management Co. LLP
5.362 %
4,415,029 5.362 % 206 M $
Sands Capital Management LLC
5.001 %
4,118,008 5.001 % 192 M $
T. Rowe Price Investment Management, Inc.
4.194 %
3,453,460 4.194 % 161 M $
T. Rowe Price International Ltd.
4.189 %
3,448,698 4.189 % 161 M $
STATE STREET CORPORATION
3.950 %
3,252,502 3.950 % 152 M $
Emil Kakkis
3.435 %
2,827,898 3.435 % 132 M $
Federated Global Investment Management Corp.
2.971 %
2,446,500 2.971 % 114 M $

Company contact information

Ultragenyx Pharmaceutical, Inc.

60 Leveroni Court

94949, Novato

+415 483 8800

http://www.ultragenyx.com
address Ultragenyx Pharmaceutical Inc.(RARE)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Sales per region

Ratings for Ultragenyx Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
43.38 USD
Average target price
90.05 USD
Spread / Average Target
+107.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ULTRAGENYX PHARMACEUTICAL INC. Stock Ultragenyx Pharmaceutical Inc.
-9.28% 3.57B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.07B
ARGENX SE Stock argenx SE
-0.44% 21.66B
BIONTECH SE Stock BioNTech SE
-18.35% 20.77B
GENMAB A/S Stock Genmab A/S
-7.45% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RARE Stock
  4. Company Ultragenyx Pharmaceutical Inc.